Hikma Pharmaceuticals (LON:HIK) Shares Down 14.1% – Here’s What Happened

Hikma Pharmaceuticals PLC (LON:HIK)’s share price was down 14.1% during trading on Thursday . The stock traded as low as GBX 1,522 and last traded at GBX 1,522. Approximately 166,325,172 shares changed hands during mid-day trading, an increase of 7,989% from the average daily volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on HIK shares. Deutsche Bank Aktiengesellschaft dropped their target price on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,600 price target on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. Berenberg Bank cut their price objective on Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating on the stock in a research note on Thursday, October 16th. Finally, JPMorgan Chase & Co. decreased their price objective on Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating on the stock in a report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of GBX 2,615.

Hikma Pharmaceuticals Trading Down 14.1%

The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The stock has a market capitalization of £3.37 billion, a price-to-earnings ratio of 9.11, a PEG ratio of 2.38 and a beta of 0.41. The business has a 50 day simple moving average of GBX 1,740.80 and a 200-day simple moving average of GBX 1,898.69.

Insider Activity at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Mazen Darwazah acquired 14,000 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was bought at an average cost of GBX 1,603 per share, with a total value of £224,420. Also, insider Laura Balan Balan purchased 3,500 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The shares were purchased at an average cost of GBX 1,821 per share, with a total value of £63,735. Corporate insiders own 17.77% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.